Literature DB >> 28049840

Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation.

William A McEwan1, Benjamin Falcon2, Marina Vaysburd2, Dean Clift2, Adrian L Oblak3, Bernardino Ghetti3, Michel Goedert1, Leo C James1.   

Abstract

Alzheimer's disease (AD) and other neurodegenerative disorders are associated with the cytoplasmic aggregation of microtubule-associated protein tau. Recent evidence supports transcellular transfer of tau misfolding (seeding) as the mechanism of spread within an affected brain, a process reminiscent of viral infection. However, whereas microbial pathogens can be recognized as nonself by immune receptors, misfolded protein assemblies evade detection, as they are host-derived. Here, we show that when misfolded tau assemblies enter the cell, they can be detected and neutralized via a danger response mediated by tau-associated antibodies and the cytosolic Fc receptor tripartite motif protein 21 (TRIM21). We developed fluorescent, morphology-based seeding assays that allow the formation of pathological tau aggregates to be measured in situ within 24 h in the presence of picomolar concentrations of tau seeds. We found that anti-tau antibodies accompany tau seeds into the cell, where they recruit TRIM21 shortly after entry. After binding, TRIM21 neutralizes tau seeds through the activity of the proteasome and the AAA ATPase p97/VCP in a similar manner to infectious viruses. These results establish that intracellular antiviral immunity can be redirected against host-origin endopathogens involved in neurodegeneration.

Entities:  

Keywords:  antibodies; immunoreceptors; intracellular immunity; neurodegeneration; tau

Mesh:

Substances:

Year:  2017        PMID: 28049840      PMCID: PMC5255578          DOI: 10.1073/pnas.1607215114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

1.  Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling.

Authors:  Natura Myeku; Catherine L Clelland; Sheina Emrani; Nikolay V Kukushkin; Wai Haung Yu; Alfred L Goldberg; Karen E Duff
Journal:  Nat Med       Date:  2015-12-21       Impact factor: 53.440

2.  Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology.

Authors:  Jiaping Gu; Erin E Congdon; Einar M Sigurdsson
Journal:  J Biol Chem       Date:  2013-10-02       Impact factor: 5.157

3.  Proteomics. Tissue-based map of the human proteome.

Authors:  Mathias Uhlén; Linn Fagerberg; Björn M Hallström; Cecilia Lindskog; Per Oksvold; Adil Mardinoglu; Åsa Sivertsson; Caroline Kampf; Evelina Sjöstedt; Anna Asplund; IngMarie Olsson; Karolina Edlund; Emma Lundberg; Sanjay Navani; Cristina Al-Khalili Szigyarto; Jacob Odeberg; Dijana Djureinovic; Jenny Ottosson Takanen; Sophia Hober; Tove Alm; Per-Henrik Edqvist; Holger Berling; Hanna Tegel; Jan Mulder; Johan Rockberg; Peter Nilsson; Jochen M Schwenk; Marica Hamsten; Kalle von Feilitzen; Mattias Forsberg; Lukas Persson; Fredric Johansson; Martin Zwahlen; Gunnar von Heijne; Jens Nielsen; Fredrik Pontén
Journal:  Science       Date:  2015-01-23       Impact factor: 47.728

4.  Distinct Therapeutic Mechanisms of Tau Antibodies: Promoting Microglial Clearance Versus Blocking Neuronal Uptake.

Authors:  Kristen E Funk; Hilda Mirbaha; Hong Jiang; David M Holtzman; Marc I Diamond
Journal:  J Biol Chem       Date:  2015-06-30       Impact factor: 5.157

5.  Swine TRIM21 restricts FMDV infection via an intracellular neutralization mechanism.

Authors:  Wenchun Fan; Dong Zhang; Ping Qian; Suhong Qian; Mengge Wu; Huanchun Chen; Xiangmin Li
Journal:  Antiviral Res       Date:  2016-01-14       Impact factor: 5.970

6.  Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease.

Authors:  M Goedert; M G Spillantini; R Jakes; D Rutherford; R A Crowther
Journal:  Neuron       Date:  1989-10       Impact factor: 17.173

Review 7.  TRIM21-dependent intracellular antibody neutralization of virus infection.

Authors:  William A McEwan; Leo C James
Journal:  Prog Mol Biol Transl Sci       Date:  2014-12-12       Impact factor: 3.622

8.  Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy.

Authors:  Asami Kondo; Koorosh Shahpasand; Rebekah Mannix; Jianhua Qiu; Juliet Moncaster; Chun-Hau Chen; Yandan Yao; Yu-Min Lin; Jane A Driver; Yan Sun; Shuo Wei; Man-Li Luo; Onder Albayram; Pengyu Huang; Alexander Rotenberg; Akihide Ryo; Lee E Goldstein; Alvaro Pascual-Leone; Ann C McKee; William Meehan; Xiao Zhen Zhou; Kun Ping Lu
Journal:  Nature       Date:  2015-07-15       Impact factor: 49.962

9.  Transmission and spreading of tauopathy in transgenic mouse brain.

Authors:  Florence Clavaguera; Tristan Bolmont; R Anthony Crowther; Dorothee Abramowski; Stephan Frank; Alphonse Probst; Graham Fraser; Anna K Stalder; Martin Beibel; Matthias Staufenbiel; Mathias Jucker; Michel Goedert; Markus Tolnay
Journal:  Nat Cell Biol       Date:  2009-06-07       Impact factor: 28.824

10.  TRIM21 Promotes cGAS and RIG-I Sensing of Viral Genomes during Infection by Antibody-Opsonized Virus.

Authors:  Ruth E Watkinson; William A McEwan; Jerry C H Tam; Marina Vaysburd; Leo C James
Journal:  PLoS Pathog       Date:  2015-10-27       Impact factor: 6.823

View more
  58 in total

Review 1.  Neuronally expressed anti-tau scFv prevents tauopathy-induced phenotypes in Drosophila models.

Authors:  Senthilkumar Krishnaswamy; Huai-Wei Huang; Isabella S Marchal; Hyung Don Ryoo; Einar M Sigurdsson
Journal:  Neurobiol Dis       Date:  2020-01-23       Impact factor: 5.996

Review 2.  Prion-like Spreading in Tauopathies.

Authors:  Jacob I Ayers; Benoit I Giasson; David R Borchelt
Journal:  Biol Psychiatry       Date:  2017-04-13       Impact factor: 13.382

Review 3.  The structure and phase of tau: from monomer to amyloid filament.

Authors:  Yifan Zeng; Jing Yang; Bailing Zhang; Meng Gao; Zhengding Su; Yongqi Huang
Journal:  Cell Mol Life Sci       Date:  2020-10-19       Impact factor: 9.261

4.  The role of wild-type tau in Alzheimer's disease and related tauopathies.

Authors:  Chih Hung Lo; Jonathan N Sachs
Journal:  J Life Sci (Westlake Village)       Date:  2020-12

5.  "Trim"ming PolyQ proteins with engineered PML.

Authors:  Neha Dhar; Ammar Arsiwala; Shruthi Murali; Ravi S Kane
Journal:  Biotechnol Bioeng       Date:  2019-11-28       Impact factor: 4.530

Review 6.  Intercellular Spread of Protein Aggregates in Neurodegenerative Disease.

Authors:  Albert A Davis; Cheryl E G Leyns; David M Holtzman
Journal:  Annu Rev Cell Dev Biol       Date:  2018-07-25       Impact factor: 13.827

Review 7.  Tau-targeting therapies for Alzheimer disease.

Authors:  Erin E Congdon; Einar M Sigurdsson
Journal:  Nat Rev Neurol       Date:  2018-07       Impact factor: 42.937

Review 8.  Tau Immunotherapies for Alzheimer's Disease and Related Tauopathies: Progress and Potential Pitfalls.

Authors:  Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

9.  Measurement of Tau Filament Fragmentation Provides Insights into Prion-like Spreading.

Authors:  Franziska Kundel; Liu Hong; Benjamin Falcon; William A McEwan; Thomas C T Michaels; Georg Meisl; Noemi Esteras; Andrey Y Abramov; Tuomas J P Knowles; Michel Goedert; David Klenerman
Journal:  ACS Chem Neurosci       Date:  2018-04-08       Impact factor: 4.418

10.  Antibody Therapy Targeting RAN Proteins Rescues C9 ALS/FTD Phenotypes in C9orf72 Mouse Model.

Authors:  Lien Nguyen; Fabio Montrasio; Amrutha Pattamatta; Solaleh Khoramian Tusi; Olgert Bardhi; Kevin D Meyer; Lindsey Hayes; Katsuya Nakamura; Monica Banez-Coronel; Alyssa Coyne; Shu Guo; Lauren A Laboissonniere; Yuanzheng Gu; Saravanakumar Narayanan; Benjamin Smith; Roger M Nitsch; Mark W Kankel; Mia Rushe; Jeffrey Rothstein; Tao Zu; Jan Grimm; Laura P W Ranum
Journal:  Neuron       Date:  2019-12-09       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.